Abstract: There is provided a method of a terminal for performing task offloading with at least one satellite in an MEC network. The method includes the steps of: acquiring at least one initial input value; acquiring information needed for determining whether or not to perform task offloading, from the at least one satellite in time slot t; setting an object function according to whether or not to perform task offloading on the basis of information on the terminal and the information needed for determining whether or not to perform task offloading acquired from the at least one satellite in time slot t; acquiring a minimum value of each object function according to whether or not to perform task offloading, and comparing the minimum value of each object function; and determining whether or not to perform task offloading to the at least one satellite in time slot t according to a result of the comparison.

Abstract: A pharmaceutical composition suitable for preventing or treating cardiac arrhythmia is disclosed. The pharmaceutical composition contains, as an active ingredient, a CCN5 protein or a nucleotide encoding the CCN5 protein. The pharmaceutical composition inhibits the pathological activity of CaMKII, which induces cardiac electrical abnormalities that is the main cause of atrial arrhythmia and ventricular arrhythmia, so as to restore the electrical functions, and inhibits the activity of myofibroblasts causing structural abnormalities. Therefore, the pharmaceutical composition can be effectively used in the prevention or treatment of cardiac arrhythmia.

Abstract: A pharmaceutical composition containing, as active ingredients, a naphthoquinone-based compound, and at least one selected from among an immune checkpoint inhibitor and an immunogenic cell death inducer, is disclosed. The pharmaceutical composition has a significantly higher anticancer effect compared to the case where each formulation is administered alone. Accordingly, an anticancer synergistic effect of inhibiting the growth in cancer cells and inhibiting the metastasis of the cancer cells, in which an anticancer effect is insignificant when the existing anticancer agent is administered alone, may be expected. Therefore, the composition containing the naphthoquinone-based compound may be usefully used as a drug for preventing or treating cancer, together with the immune checkpoint inhibitor and/or the immunogenic cell death inducer.

Abstract: Disclosed are a compound represented by Formula (1) below, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R3,and Xi to X6 are the same as defined in claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in claim 1.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cardiac arrhythmia. Particularly, the present invention relates to a pharmaceutical composition containing, as an active ingredient, a CCN5 protein or a nucleotide encoding the same. The pharmaceutical composition for preventing or treating cardiac arrhythmia, of the present invention, inhibits the pathological activity of CaMKII, which induces cardiac electrical abnormalities which is the main cause of atrial arrhythmia and ventricular arrhythmia, so as to restore the electrical functions, and inhibits the activity of myofibroblasts causing structural abnormalities. Therefore, the pharmaceutical composition of the present invention can be effectively used in the prevention or treatment of cardiac arrhythmia.

Abstract: The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in Claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R3, and X1 to X6 are the same as defined in Claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in Claim 1.

Abstract: The present invention relates to a composition for treating or preventing hearing loss comprising naphthoquinone-based compounds.

Abstract: A cooling system for a low pressure casting device, which includes an upper mold provided with a core portion of a spark plug and an upper die, a lower mold provided with a mold portion of a combustion chamber and a lower die, and side molds, may include i) a coolant supply unit connected respectively to the core portion of the spark plug, the upper die, the mold portion of the combustion chamber, and the lower die through coolant supply lines, ii) a cooling air supply unit connected respectively to the side molds and the mold portion of the combustion chamber through air supply lines, and iii) a vacuum intake unit connected respectively to the core portion of the spark plug, the upper die, the mold portion of the combustion chamber, and the lower die through vacuum intake lines.

Abstract: Provided is a composition that contains, as an active ingredient, an extract or polysaccharides separated from the leaves and/or stems of plants belonging to Panax genus, for an anticancer drug or its adjuvant, having an effect on the activity of hematopoiesis enhancement, cancer metastasis inhibition, bone marrow defense, etc. . . . , and a process for preparation of the extract from the leaves and/or stems of plants belonging to Panax genus.

Abstract: A cooling system for a low pressure casting device, which includes an upper mold provided with a core portion of a spark plug and an upper die, a lower mold provided with a mold portion of a combustion chamber and a lower die, and side molds, may include i) a coolant supply unit connected respectively to the core portion of the spark plug, the upper die, the mold portion of the combustion chamber, and the lower die through coolant supply lines, ii) a cooling air supply unit connected respectively to the side molds and the mold portion of the combustion chamber through air supply lines, and iii) a vacuum intake unit connected respectively to the core portion of the spark plug, the upper die, the mold portion of the combustion chamber, and the lower die through vacuum intake lines.

Abstract: The present invention relates to novel imidazole derivatives which show an inhibitory activity against farnesyl transferase, pharmaceutically acceptable salts or isomers thereof and pharmaceutical compositions comprising such imidazole derivatives. More particularly, the present invention relates to intermediate compounds which are used in the preparation of the imidazole derivatives of the invention. Related processes also are disclosed.

Abstract: The present invention relates to a novel imidazole derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in which A, n1 and Y are defined in the specification; to a process for preparation of the compound of formula (1); to intermediates which are used in the preparation of the compound of formula (1): and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.

Abstract: The present invention relates to novel imidazole derivatives which show an inhibitory activity against farnesyl transferase, pharmaceutically acceptable salts or isomers thereof and pharmaceutical compositions comprising such imidazole derivatives. More particularly, the present invention relates to intermediate compounds which are used in the preparation of the imidazole derivatives of the invention. Related processes also are disclosed.

Abstract: The present invention relates to a novel piperidine derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts thereof, in which A, E and G are defined in the specification; to a process for preparation of the compound of formula (1); to an intermediate which is used in the preparation of the compound of formula (1); and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.

Abstract: The present invention relates to novel hydantoin compounds represented by formula (I) which shows an inhibitory activity against farnesyl transferase, and thus can be used as an anti-cancer agent, or pharmaceutically acceptable salts thereof, in which R1, R2, R3 and R4 are as defined in the present application. The present invention also relates to a process for preparation of the compound of formula (I), and to an anti-cancer composition comprising the compound of formula (I) as an active ingredient.